Strong oncology, obesity, and cardiovascular drug candidates behind rating upgrade
Amgen Inc.’s AMGN, -0.11% pipeline of cancer, obesity and cardiovascular drugs is poised to deliver good news for the stock, analysts say, despite the company’s recent setback with cancer drug Lumakras.
Leerink Partners analysts on Wednesday upgraded Amgen shares to outperform from market perform, saying “accelerating pipeline newsflow” would bolster the stock’s valuation. Amgen has several potential blockbuster cancer-drug candidates set to make news in the coming weeks, the analysts wrote, including AMG 193, being studied for treatment of non-small cell lung cancer, and xaluritamig, designed to treat prostate cancer.
The Leerink analysts slashed their 2031 Lumakras sales estimates 76%, to $153 million, saying there’s a risk the FDA could rescind its tentative approval of the drug as results of the confirmatory trial are under scrutiny. Even so, the analysts wrote, Amgen’s broader pipeline potential, combined with its acquisition of Horizon Therapeutics, should continue to boost earnings expectations.
Amgen shares climbed 1% premarket on Wednesday and have gained 3.3% in the year to date, while the S&P 500 SPX is up 13.5%.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Adds Warning To Ozempic Label About Ileus, Intestinal BlockageI am a writer, journalist, professor, systems modeler, computational, AI, and digital health expert, medical doctor, avocado-eater, and entrepreneur, not always in that order. Currently, I am a Professor of Health Policy and Management at the City University of New York (CUNY) School of Public Health, Executive Director of PHICOR (PHICORteam) and Center for Advanced Technology and Communication in Health (CATCH), and founder and CEO of Symsilico. My previous positions include serving as Profess
Read more »
Novavax ships millions of updated COVID-19 vaccine doses after FDA clearanceVaccine manufacturer Novavax Inc. has announced the shipment of millions of doses of its updated COVID-19 vaccines to distributors following approval from U.S. regulators.
Read more »
Alnylam gives up on expanded use of heart-disease drug in US after FDA declines approvalAlnylam Pharmaceuticals (ALNY.O) said on Monday it would not pursue expanded use of its drug to treat a potentially fatal heart disease in the U.S. after the Food and Drug Administration declined to approve the medication despite a favorable recommendation from its advisers.
Read more »
FDA Approves Intravenous Formulation of SecukinumabThis new route of administration is expected to become available during the fourth quarter of 2023.
Read more »
Supreme Court declines to hear case challenging FDA authority to reject flavored e-cigarettesAvail Vapor's case is one of several challenges to the FDA's regulation of the vaping industry, which has hooked a new generation on nicotine in the U.S.
Read more »
Hair Relaxers Could Be Banned as Part of FDA CrackdownThe move will help 'Black women who are disproportionately put at risk by these products as a result of systemic racism,' one campaigner says.
Read more »